News

Aridis Names New Chief Medical Officer To Lead Development of CF Treatment of Pseudomonas Aeruginosa

Biopharmaceutical company Aridis Pharmaceuticals, Inc. has named Paul-Andre de Lame, MD as its new chief medical officer to help the company in their efforts to develop new anti-infective and immune therapies to treat infectious diseases. Aridis is currently developing a reactive monoclonal antibody drug called Aerucin, to treat Pseudomonas aeruginosa associated with cystic fibrosis.

AbbVie Scholarship For Students With CF Now Accepting Applications

AbbVie recently announced that the 2015 AbbVie CF Scholarship is now open and accepting applications from both graduate and undergraduate students. This scholarship supports and honors young adults suffering with cystic fibrosis (CF) in their pursuit of higher education. Students can apply for the scholarship until May 27, 2015, 10 a.m. (central…

Crystal Climbs for CF: Hiking Against the Odds

As a chronic disease that causes difficulties in breathing, persistent coughing, thick mucus and wheezing, most patients with cystic fibrosis (CF) struggle to manage the symptoms, often making exercise extremely difficult. 23 year-old Crystal Park, however, decided to take control of her body and the disease and, despite the difficulties,…

Cambridge Researchers Create Mini-Lungs For CF Research

Branching mini-lung. Credit: Nick Hannan, University of Cambridge The creation of a pair of mini-lungs was successfully completed by a group of investigators at the University of Cambridge and may revolutionize the treatment of conditions that affect the pulmonary system. The mini-lungs were created as part of a…

Recent Cystic Fibrosis Research on Vertex’s Kalydeco Disappoints Investors

Vertex Pharmaceuticals Inc. recently presented preliminary study results of FDA-approved Kalydeco for the treatment of cystic fibrosis (CF) in combination with an investigational drug. Despite the fact that the combined therapy helped improve breathing in CF patients, the outcomes were less significant than expected by analysts, which disappointed investors. Vertex conducted…